Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Argenx (ARGX) to EUR 650 from EUR 715 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- Argenx announces European Commission approval of VYVGART subcutaneous injection
- Promising Clinical Trial Results and Strategic Pipeline Development Position Argenx Se as a Strong Investment Prospect
- Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases
- Argenx presents new Efgartigimod data at EULAR 2025